Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease

Future Microbiology

Volumn 10, Issue 5, 2015, Pages 889-902

  Tarantino, Giovanni ^a,b   Finelli, Carmine ^c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c Stella Maris Mediterraneum Foundation   (Italy)

Author keywords

gut microbiota; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; obesity; prebiotics; probiotics

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PREBIOTIC AGENT; PROBIOTIC AGENT;

DATA BASE; EMBASE; HUMAN; LITERATURE; MEDICAL SUBJECT HEADINGS; MEDLINE; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; BIOLOGICAL THERAPY; COMPLICATION; NON-ALCOHOLIC FATTY LIVER DISEASE; PROCEDURES;

BIOLOGICAL THERAPY; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PREBIOTICS; PROBIOTICS;

EID: 84929716124     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.15.13     Document Type: Review

References (68)

1. Cénit MC, Matzaraki V, Tigchelaar EF, Zhernakova A. Rapidly expanding knowledge on the role of the gut microbiome in health and disease. Biochim. Biophys. Acta 1842(10), 1981-1992 (2014).
2. Frick JS, Autenrieth IB. The gut microflora and its variety of roles in health and disease. Curr. Top. Microbiol. Immunol. 358, 273-289 (2013).
3. Finelli C, Tarantino G. Non-alcoholic fatty liver disease, diet and gut microbiota. EXCLI Journal 13, 461-490 (2014).
4. Xiao S, Zhao L. Gut microbiota-based translational biomarkers to prevent metabolic syndrome via nutritional modulation. FEMS Microbiol. Ecol. 87(2), 303-314 (2014).
5. Sweeney TE, Morton JM. The human gut microbiome: a review of the effect of obesity and surgically induced weight loss. JAMA Surg. 148(6), 563-569 (2013).
6. Kim JH. The physical activity level in female affects colon transit time. J. Neurogastroenterol. Motil. 18(1), 4-5 (2012).
7. Cho KO, Jo YJ, Song BK, Oh JW, Kim YS. Colon transit time according to physical activity and characteristics in South Korean adults. World J. Gastroenterol. 19(4), 550-555 (2013).
8. Valdés-Ramos R, Martínez-Carrillo BE, Aranda-González II et al. Diet, exercise and gut mucosal immunity. Proc. Nutr. Soc. 69(4), 644-650 (2010).
9. Clarke SF, Murphy EF, O'Sullivan O et al. Exercise and associated dietary extremes impact on gut microbial diversity. Gut 63(12), 1913-1920 (2014).
10. Tarantino G, Finelli C. What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome? World J. Gastroenterol. 19(22), 3375-3384 (2013).
11. Fierbinteanu-Braticevici C, Negreanu L, Tarantino G. Is fatty liver always benign and should not consequently be treated? J. Physiol. Pharmacol. 64(1), 3-9 (2013).
12. Raman M, Allard J. Non alcoholic fatty liver disease: a clinical approach and review. Can. J. Gastroenterol. 20(5), 345-349 (2006).
13. Pan JJ, Fallon MB. Gender and racial differences in nonalcoholic fatty liver disease. World J. Hepatol. 6(5), 274-283 (2014).
14. Tarantino G. Gut microbiome, obesity-related comorbidities, and low-grade chronic inflammation. J. Clin. Endocrinol. Metab. 99(7), 2343-2346 (2014).
15. Remely M, Aumueller E, Merold C et al. Effects of short chain fatty acid producing bacteria on epigenetic regulation of FFAR3 in Type 2 diabetes and obesity. Gene 537(1), 85-92 (2014).
16. Chen Z, Guo L, Zhang Y et al. Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity. J. Clin. Invest. 124(8), 3391-3406 (2014).
17. Li M, Gu D, Xu N et al. Gut carbohydrate metabolism instead of fat metabolism regulated by gut microbes mediates high-fat diet-induced obesity. Benef. Microbes 5(3), 335-344 (2014).
18. Walker A, Pfitzner B, Neschen S et al. Distinct signatures of host-microbial meta-metabolome and gut microbiome in two C57BL/6 strains under high-fat diet. ISME J. 8(12), 2380-2396 (2014).
19. Karlsson F, Tremaroli V, Nielsen J, Bäckhed F. Assessing the human gut microbiota in metabolic diseases. Diabetes 62(10), 3341-3349 (2013).
20. Tomaro-Duchesneau C, Saha S, Malhotra M et al. Effect of orally administered L. fermentum NCIMB 5221 on markers of metabolic syndrome: an in vivo analysis using ZDF rats. Appl. Microbiol. Biotechnol. 98(1), 115-126 (2014).
21. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int. J. Surg. 8(5), 336-341. (2010).
22. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org
23. Mykhal'chyshyn HP, Bodnar PM, Kobyliak NM. [Effect of probiotics on proinflammatory cytokines level in patients with Type 2 diabetes and non-alcoholic fatty liver disease]. Lik. Sprava 2, 56-62 (2013).
24. Wong VW, Won GL, Chim AM et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann. Hepatol. 12(2), 256-262 (2013).
25. Aller R, De Luis DA, Izaola O et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. Eur. Rev. Med. Pharmacol. Sci. 15(9), 1090-1095 (2011).
26. Dewulf EM, Cani PD, Claus SP et al. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 62(8), 1112-1121 (2013).
27. de Luis DA, de la Fuente B, Izaola O et al. Double blind randomized clinical trial controlled by placebo with an alpha linoleic acid and prebiotic enriched cookie on risk cardiovascular factor in obese patients. Nutr. Hosp. 26(4), 827-833 (2011).
28. de Luis DA, de la Fuente B, Izaola O et al. Randomized clinical trial with a inulin enriched cookie on risk cardiovascular factor in obese patients. Nutr. Hosp. 25(1), 53-59 (2010).
29. Balcázar-Muñoz BR, Martínez-Abundis E, González-Ortiz M. Effect of oral inulin administration on lipid profile and insulin sensitivity in subjects with obesity and dyslipidemia. Rev. Med. Chil. 131(6), 597-604 (2003).
30. Karlsson Videhult F, Ohlund I, Stenlund H, Hernell O, West CE. Probiotics during weaning: a follow-up study on effects on body composition and metabolic markers at school age. Eur J Nutr. 17 (2014) (Epub ahead of print).
31. Alisi A, Bedogni G, Baviera G et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with nonalcoholic steatohepatitis. Aliment. Pharmacol. Ther. 39(11), 1276-1285 (2014).
32. Sanchez M, Darimont C, Drapeau V et al. Effect of Lactobacillus rhamnosus CGMCC1.3724 supplementation on weight loss and maintenance in obese men and women. Br. J. Nutr. 111(8), 1507-1519 (2014).
33. Zarrati M, Salehi E, Mofid V et al. Relationship between probiotic consumption and IL-10 and IL-17 secreted by PBMCs in overweight and obese people. Iran J. Allergy Asthma Immunol. 12(4), 404-406 (2013).
34. Kadooka Y, Sato M, Ogawa A et al. Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial. Br. J. Nutr. 110(9), 1696-1703 (2013).
35. Safavi M, Farajian S, Kelishadi R, Mirlohi M, Hashemipour M. The effects of synbiotic supplementation on some cardio-metabolic risk factors in overweight and obese children: a randomized triple-masked controlled trial. Int. J. Food Sci. Nutr. 64(6), 687-693 (2013).
36. Nitert MD, Barrett HL, Foxcroft K et al. SPRING: an RCT study of probiotics in the prevention of gestational diabetes mellitus in overweight and obese women. BMC Pregnancy Childbirth 13, 215158 (2013).
37. Chorell E, Karlsson Videhult F, Hernell O, Antti H, West CE. Impact of probiotic feeding during weaning on the serum lipid profile and plasma metabolome in infants. Br. J. Nutr. 110(1), 116-126 (2013).
38. Leber B, Tripolt NJ, Blattl D et al. The influence of probiotic supplementation on gut permeability in patients with metabolic syndrome: an open label, randomized pilot study. Eur. J. Clin. Nutr. 66(10), 1110-1115 (2012).
39. Gøbel RJ, Larsen N, Jakobsen M, Mølgaard C, Michaelsen KF. Probiotics to adolescents with obesity: effects on inflammation and metabolic syndrome. J. Pediatr. Gastroenterol. Nutr. 55(6), 673-678 (2012).
40. Mikirova NA, Casciari JJ, Hunninghake RE, Beezley MM. Effect of weight reduction on cardiovascular risk factors and CD34-positive cells in circulation. Int. J. Med. Sci. 8(6), 445-452 (2011).
41. Vajro P, Mandato C, Licenziati MR et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J. Pediatr. Gastroenterol. Nutr. 52(6), 740-743 (2011).
42. Ilmonen J, Isolauri E, Poussa T, Laitinen K. Impact of dietary counselling and probiotic intervention on maternal anthropometric measurements during and after pregnancy: a randomized placebo-controlled trial. Clin. Nutr. 30(2), 156-164 (2011).
43. Luoto R, Kalliomäki M, Laitinen K, Isolauri E. The impact of perinatal probiotic intervention on the development of overweight and obesity: follow-up study from birth to 10 years. Int. J. Obes. (Lond.) 34(10), 1531-1537 (2010).
44. Kadooka Y, Sato M, Imaizumi K et al. Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial. Eur. J. Clin. Nutr. 64(6), 636-643 (2010).
45. Luoto R, Laitinen K, Nermes M, Isolauri E. Impact of maternal probiotic-supplemented dietary counselling on pregnancy outcome and prenatal and postnatal growth: a double-blind, placebo-controlled study. Br. J. Nutr. 103(12), 1792-1799 (2010).
46. Woodard GA, Encarnacion B, Downey JR et al. Probiotics improve outcomes after Roux-en-Y gastric bypass surgery: a prospective randomized trial. J. Gastrointest. Surg. 13(7), 1198-1204 (2009).
47. Agerholm-Larsen L, Raben A, Haulrik N et al. Effect of 8 week intake of probiotic milk products on risk factors for cardiovascular diseases. Eur. J. Clin. Nutr. 54(4), 288-297 (2000).
48. Amenta M, Cascio MT, Di Fiore P, Venturini I. Diet and chronic constipation. Benefits of oral supplementation with symbiotic zir fos (Bifidobacterium longum W11 + FOS Actilight). Acta Biomed. 77(3), 157-162 (2006).
49. Huet F, Lachambre E, Beck L, Van Egroo LD, Sznajder M. [Evaluation of a formula with low protein content and supplemented with probiotic agents after breast milk weaning]. Arch. Pediatr. 13(10), 1309-1315 (2006).
50. Santacruz A, Marcos A, Wärnberg J et al. Interplay between weight loss and gut microbiota composition in overweight adolescents. Obesity (Silver Spring) 17, 1906-1915 (2009).
51. Osto M, Abegg K, Bueter M, le Roux CW, Cani PD, Lutz TA. Roux-en-Y gastric bypass surgery in rats alters gut microbiota profile along the intestine. Physiol. Behav. 119, 92-96 (2013).
52. Hermes GD, Zoetendal EG, Smidt H. Molecular ecological tools to decipher the role of our microbial mass in obesity. Benef. Microbes 6(1), 61-81 (2014).
53. Martinez-Gonzalez MA, Sayon-Orea C, Ruiz-Canela M, de la Fuente C, Gea A, Bes-Rastrollo M. Yogurt consumption, weight change and risk of overweight/obesity: The SUN cohort study. Nutr. Metab. Cardiovasc. Dis. 24(11), 1189-1196 (2014).
54. Jacques PF, Wang H. Yogurt and weight management. Am. J. Clin. Nutr. 99(5), 1229-1234 (2014).
55. Prentice AM, Jebb SA. Beyond body mass index. Obes. Rev. 2(3), 141-147 (2001).
56. Sun Q, van Dam RM, Spiegelman D, Heymsfield SB, Willett WC, Hu FB. Comparison of dual-energy x-ray absorptiometric and anthropometric measures of adiposity in relation to adiposity-related biologic factors. Am. J. Epidemiol. 172(12), 1442-1454 (2010).
57. Hamdy O, Porramatikul S, Al-Ozairi E. Metabolic obesity: the paradox between visceral and subcutaneous fat. Curr. Diabetes Rev. 2(4), 367-373 (2006).
58. Pischon T, Boeing H, Hoffmann K et al. General and abdominal adiposity and risk of death in Europe. N. Engl. J. Med. 359(20), 2105-2120 (2008).
59. Cerhan JR, Moore SC, Jacobs EJ et al. A pooled analysis of waist circumference and mortality in 650,000 adults. Mayo Clin Proc. 89(3), 335-345 (2014).
60. Gomes AC, Bueno AA, de Souza RG, Mota JF. Gut microbiota, probiotics and diabetes. Nutr. J. 13, 215158 (2014).
61. Bolnick DI, Snowberg LK, Hirsch PE et al. Individual diet has sex-dependent effects on vertebrate gut microbiota. Nat. Commun. 5, 215158 (2014).
62. Stenman LK, Waget A, Garret C, Klopp P, Burcelin R, Lahtinen S. Potential probiotic Bifidobacterium animalis ssp. lactis 420 prevents weight gain and glucose intolerance in diet-induced obese mice. Benef. Microbes 1, 215158 (2014).
63. Hanage WP. Microbiology: microbiome science needs a healthy dose of scepticism. Nature 512(7514), 247-248 (2014).
64. Shanahan F. The microbiota in inflammatory bowel disease: friend, bystander, and sometime-villain. Nutr. Rev. 70(1), 31-37 (2012).
65. Iacono A, Raso GM, Canani RB, Calignano A, Meli R. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J. Nutr. Biochem. 22(8), 699-711 (2011).
66. Eslamparast T, Eghtesad S, Hekmatdoost A, Poustchi H. Probiotics and nonalcoholic fatty liver disease. Middle East J. Dig. Dis. 5(3), m129-m136 (2013).
67. Tuohy KM, Probert HM, Smejkal CW, Gibson GR. Using probiotics and prebiotico to improve gut health. Drug Discov. Today 8(15), 692-700 (2003).
68. Sánchez de Medina F, Romero-Calvo I, Mascaraque C, Martínez-Augustin O. Intestinal inflammation and mucosal barrier function. Inflamm. Bowel Dis. 20(12), 2394-2404 (2014).